Skip to main content
Premium Trial:

Request an Annual Quote

Zyomyx Sells Protein Profiling Biochip System to Aventis

NEW YORK, March 6 - Zyomyx today said that Aventis has agreed to buy one of its Protein Profiling Biochip systems.

The tool consists of Zyomyx's first protein profiling biochip--called the Human Cytokine Biochip--as well as the Assay 1200 automated workstation and the Scanner 100 reader and data-analysis software.

Zyomyx said Aventis will apply the Protein Profiling Biochip System and Human Cytokine Biochips to its R&D programs in inflammation.

Financial details were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more